PatentJul 15, 2026, 08:01 AM
Autonomix Medical Receives Patent for Overactive Bladder Treatment
AI Summary
Autonomix Medical, Inc. announced the issuance of U.S. Patent No. 12,611,134, titled "Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder." This patent significantly expands the company's proprietary neural sensing and therapeutic technology into the large urology market, targeting a condition that affects approximately 37 million Americans. The new patent reinforces Autonomix's strategy of developing organ-specific applications from its scalable core technology and brings its total intellectual property portfolio to 112 issued or pending patent applications globally.
Key Highlights
- Autonomix Medical received U.S. Patent No. 12,611,134 for "Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder."
- The patent expands the company's neural sensing and therapeutic technology into urology for Overactive Bladder (OAB).
- OAB affects an estimated 37 million Americans, representing a significant clinical market.
- The company's intellectual property portfolio now includes 112 issued or pending patent applications worldwide.
- The patented system is catheter-based, designed for minimally invasive access to sense and treat OAB at the bladder wall.
- The patent covers targeted therapy delivery using radiofrequency ablation, thermal energy, ultrasonic energy, or localized therapeutic agents.
- An implantable, self-contained bladder device for long-term monitoring and sustained local drug-release is also covered.
Price Impact
More from AMIX